Dr. Lillian Siu has over 20 years of experience as a senior medical oncologist at Princess Margaret Cancer Centre, as well as experience as a Professor of Medicine at the University of Toronto. Dr. Siu’s main research focus is in precision oncology, biomarkers especially circulating tumor DNA and clinical trials methodology. She is the Director of the Phase I Program, Co-Director of the Bras and Family Drug Development Program, and Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu is currently the Editor-in-Chief for American Association for Cancer Research’s newest journal Cancer Research Communications. She is also a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology, Cell and Cancer Cell. Dr. Siu earned her MD from the University of Toronto.

Dr. Howard Kaufman has over 25 years of experience in cancer immunotherapy and drug development. Previously, he served as a Society for Immunotherapy of Cancer (SITC) President and is currently the President and Chief Executive Officer at Ankyra Therapeutics. In addition, he served as a Clinical Associate at Massachusetts General Hospital. His research focuses on developing oncolytic viruses and immunotherapy for the treatment of melanoma and other cutaneous malignancies. His work has led to the FDA approval of the first oncolytic virus in cancer treatment, and established the importance of anti-PD-L1 treatment for advanced Merkel cell carcinoma. His lab continues to advance our understanding of how viruses induce immunogenic cell death and initiate host anti-tumor immunity. Dr. Kaufman earned his MD from Loyola University Chicago.

Dr. Aurélien Marabelle is a physician scientist who brings expertise in oncology and immunology to Marengo. He currently is Director of the Clinical Investigation Center BIOTHERIS focusing on intratumoral immunotherapies, full professor of Clinical Immunology at the University of Paris Saclay, and leader of a translational research laboratory within the National Institute of Health and Medical Research (INSERM), focusing on mechanisms of action of immune targeted therapies. He also leads a clinical practice dedicated to early phase clinical trials of cancer immunotherapies within the Drug Development Department of the Gustave Roussy Cancer Center in France. He is the current President of the French Society for Cancer Immunotherapies. Dr. Marabelle earned his PhD in Oncology and Immunology at Ecole Normale Supérieure de Lyon, King’s College London, and University of Lyon. He trained at the University of Paris VI medical school and received his M.D. from the University of Clermont-Ferrand.